Division of Clinical Epidemiology, Department of Medicine, Solna.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm.
Rheumatology (Oxford). 2023 Mar 1;62(3):1170-1178. doi: 10.1093/rheumatology/keac474.
To conduct the first-ever nationwide, population-based cohort study investigating survival patterns of all patients with incident SSc in Sweden compared with matched individuals from the Swedish general population.
We used the National Patient Register to identify patients with incident SSc diagnosed between 2004 and 2015 and the Total Population Register to identify comparators (1:5), matched on sex, birth year and residential area. We followed them until death, emigration or the end of 2016. Follow-up of the general population comparators started the same date as their matched patients were included. We estimated all-cause survival using the Kaplan-Meier method, crude mortality rates and hazard ratios (HRs) using flexible parametric models.
We identified 1139 incident patients with SSc and 5613 matched comparators. The median follow-up was 5.0 years in patients with SSc and 6.0 years for their comparators. During follow-up, 268 deaths occurred in patients with SSc and 554 in their comparators. The 5-year survival was 79.8% and the 10-year survival was 67.7% among patients with SSc vs 92.9% and 84.8%, respectively, for the comparators (P < 0.0001). The mortality rate in patients with SSc was 42.1 per 1000 person-years and 15.8 per 1000 person-years in their comparators, corresponding to an HR of 3.7 (95% CI 2.9, 4.7) at the end of the first year of follow-up and 2.0 (95% CI 1.4, 2.8) at the end of the follow-up period.
Despite advances in understanding the disease and in diagnostic methods over the past decades, survival is still severely impacted in Swedish patients diagnosed with SSc between 2004 and 2015.
开展首次全国范围内基于人群的队列研究,调查瑞典所有新发系统性硬化症(SSc)患者的生存模式,并与瑞典普通人群中的匹配个体进行比较。
我们使用国家患者登记处来识别 2004 年至 2015 年间诊断为新发 SSc 的患者,并使用全人群登记处来识别(1:5)匹配的对照者,匹配性别、出生年份和居住地区。我们对他们进行随访,直至死亡、移民或 2016 年底。普通人群对照者的随访从与他们匹配的患者被纳入的那一天开始。我们使用 Kaplan-Meier 方法估计全因生存率,使用灵活参数模型估计粗死亡率和危险比(HRs)。
我们确定了 1139 例新发 SSc 患者和 5613 名匹配对照者。SSc 患者的中位随访时间为 5.0 年,其对照者为 6.0 年。在随访期间,SSc 患者中有 268 人死亡,其对照者中有 554 人死亡。SSc 患者的 5 年生存率为 79.8%,10 年生存率为 67.7%,而其对照者的生存率分别为 92.9%和 84.8%(P<0.0001)。SSc 患者的死亡率为 42.1/1000 人年,其对照者为 15.8/1000 人年,相应的第一年随访结束时的 HR 为 3.7(95%CI 2.9, 4.7),随访结束时的 HR 为 2.0(95%CI 1.4, 2.8)。
尽管在过去几十年中对疾病和诊断方法的认识有所提高,但 2004 年至 2015 年间在瑞典诊断为 SSc 的患者的生存仍然受到严重影响。